Trial Profile
IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2013
Price :
$35
*
At a glance
- Drugs Abciximab (Primary)
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms IC-CLEARLY
- 01 Jun 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 May 2009 New trial record